Regentis Biomaterials Plans European Surgeon Training for GelrinC Rollout

Regentis Biomaterials (NYSE American: RGNT) is taking a major step toward commercializing its innovative knee cartilage treatment, GelrinC(R), by announcing plans to launch European surgeon training activities in the third quarter of 2026. The hands-on program will provide orthopedic surgeons with practical experience using the company’s cell-free implant, beginning at Humanitas Research Hospital in Milan, Italy, with additional sessions planned across Europe. This training initiative is a cornerstone of Regentis’ European commercialization strategy and will be supported by a network of Centers of Excellence focused on surgeon education, clinical guidance, and knowledge sharing. GelrinC is designed as a ready-to-use, single-step implant procedure for knee cartilage repair, and Regentis believes that expanding physician familiarity with the technology will drive adoption as the product enters broader clinical use. The company is targeting a market of approximately 470,000 cases for cartilage knee repair annually in the U.S., where no off-the-shelf treatment is currently available.

GelrinC is a cell-free, off-the-shelf hydrogel that is eroded and resorbed in the knee, allowing surrounding cells to regenerate cartilage in a controlled, synchronous process. This approach addresses a significant unmet need in orthopedic medicine, as current treatments often require multiple surgeries or cell-based therapies. Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing innovative tissue repair solutions, with its Gelrin platform technology based on synchronized, degradable hydrogel implants that regenerate damaged or diseased tissue, including inflamed cartilage and bone. The company’s lead product, GelrinC, has received CE Mark approval, positioning it for commercialization in Europe. To view the full press release, visit https://ibn.fm/QOWWK.

The training program is expected to play a critical role in ensuring that surgeons are proficient in the GelrinC procedure, which could lead to better patient outcomes and faster adoption. Regentis is also leveraging its network of Centers of Excellence to support ongoing education and knowledge sharing among orthopedic specialists. As the company prepares for commercial rollout, investor attention is focused on the potential of GelrinC to disrupt the knee cartilage repair market. For the latest news and updates relating to RGNT, visit https://ibn.fm/RGNT. The announcement underscores Regentis’ commitment to advancing regenerative medicine and providing a much-needed off-the-shelf solution for patients suffering from knee cartilage lesions.